Published in Women's Health Weekly, June 24th, 1996
Eli Lilly continues to retain exclusive rights to the BRCA1 gene, which it licensed from Myriad Genetics, Inc. for use in developing therapeutic products. "... work in our collaboration and in the field by ourselves and others has underscored the potential importance of BRCA1 in breast and ovarian cancer," said Hollings Renton, Onyx. "As a result, we are broadening this collaboration to enhance our understanding of BRCA1-related...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly